Tag Archives: nivolumab

Opdivo for Mesothelioma Recurrence is Safe and Effective, Study Finds

Opdivo for mesothelioma recurrence

A new Japanese study appears to show that Opdivo for mesothelioma recurrence after surgery is safe and effective.  Opdivo (nivolumab) is an immunotherapy drug similar to Keytruda (pembrolizumab). It blocks a protein called PD-L1. PD-L1 helps mesothelioma cells avoid detection by the immune system.  In the latest study, 35 patients received Opdivo for mesothelioma recurrence. More than three quarters of them experienced either stable or decreased disease. Understanding How Nivolumab Works Nivolumab is most often used to treat non-small cell lung cancer. It makes tumors more vulnerable to immune system attack. Pleural mesothelioma has many of the same characteristics as lung cancer. This is one reason researchers are hopeful about Opdivo for mesothelioma recurrence.  The primary treatment for mesothelioma is … Continue reading Opdivo for Mesothelioma Recurrence is Safe and Effective, Study Finds »

Rare But Dangerous Side Effects of Opdivo for Mesothelioma

side effects of Opdivo

Australian researchers are warning of some rare but deadly side effects of Opdivo (nivolumab) for pleural mesothelioma.  They have just published a case report of a mesothelioma patient on nivolumab, a drug often used to treat lung cancer. The patient developed swelling of the heart and other muscles. The swelling lasted for months, even after they stopped taking the drug.  The case report details the healthcare teams’ effort to manage these potentially lethal side effects of Opdivo. They caution that other immune checkpoint inhibitors might cause similar complications. How Opdivo Fights Mesothelioma The primary treatment for mesothelioma is chemotherapy with pemetrexed (Alimta). Eventually, most patients stop responding to chemotherapy. At that point, doctors may turn to an immunotherapy drug like … Continue reading Rare But Dangerous Side Effects of Opdivo for Mesothelioma »

PD-L1 Inhibitor Nivolumab Works Well in New Mesothelioma Study

PD-L1 inhibitor nivolumab

A study of the PD-L1 inhibitor nivolumab showed “safety and efficacy” in mesothelioma patients who failed with other treatments.  Nivolumab is a type of immunotherapy marketed under the brand name Opdivo. It is similar to pembrolizumab (Keytruda) in that it blocks the tumor-promoting protein PD-L1. Nivolumab is most often used for patients with non-small cell lung cancer.  A multicenter phase II Japanese study found the PD-L1 inhibitor nivolumab helped a group of pleural mesothelioma patients live longer. Just as importantly, the side effects of the drug were “manageable”.  Human Trial of PD-L1 Inhibitor Nivolumab Chemotherapy with pemetrexed (Alimta) and cisplatin is the standard first-line treatment for pleural mesothelioma. But many patients either do not respond to chemotherapy or they stop … Continue reading PD-L1 Inhibitor Nivolumab Works Well in New Mesothelioma Study »

Immunotherapy Prompts “Remarkable Response” in Sarcomatoid Pleural Mesothelioma

sarcomatoid pleural mesothelioma

Japanese doctors are reporting a remarkable response from the immunotherapy drug nivolumab in a patient with sarcomatoid pleural mesothelioma.  Sarcomatoid pleural mesothelioma is a very rare form of a rare cancer. It accounts for about 10 percent of cases of malignant mesothelioma.  This subtype is typically less responsive to standard treatments than the more common epithelioid variety. But researches at Kyushu Hospital in Fukuoka, Japan say nivolumab turned things around for their patient when the case looked hopeless.  How is Sarcomatoid Pleural Mesothelioma DIfferent? Malignant mesothelioma is a cancer of the linings around organs. Pleural mesothelioma grows on the pleural membrane that surrounds the lungs.  There are three cell subtypes of mesothelioma. The three subtypes respond differently to mesothelioma treatments. … Continue reading Immunotherapy Prompts “Remarkable Response” in Sarcomatoid Pleural Mesothelioma »

Mesothelioma Tumor Response to Nivolumab Detailed in New Case Study

mesothelioma tumor response to nivolumab

An Indian woman in still alive two years after a mesothelioma diagnosis thanks to a remarkable mesothelioma tumor response to nivolumab. Nivolumab is sold under the brand name Opdivo. It is a type of immunotherapy. Nivolumab is sometimes used for lung cancer that progresses after chemotherapy. A hospital in Mumbai tried nivolumab on a pleural mesothelioma patient after several types of chemotherapy did not work. Doctors say the mesothelioma tumor response to nivolumab was so great that the patient no longer needed supplemental oxygen.  Opdivo in Mesothelioma Treatment Opdivo is not FDA-approved for mesothelioma treatment. Only Alimta (pemetrexed) holds that designation. But pleural mesothelioma grows quickly and is hard to treat. Even the gold standard therapies often do not work … Continue reading Mesothelioma Tumor Response to Nivolumab Detailed in New Case Study »

New Mesothelioma Immunotherapy Trial Now Underway at Baylor

mesothelioma clinical trial results

Cancer researchers at Baylor College of Medicine have launched a new mesothelioma immunotherapy trial. The trial combines the cancer drug Opdivo (nivolumab) with injections of a modified virus called MTG201. Baylor scientists are hoping to recruit 12 pleural mesothelioma patients whose cancer has come back after chemotherapy.  The treatment combination appeared to work well in mice with mesothelioma. If it works as well in people, this new mesothelioma immunotherapy trial could change the outlook for many people with malignant mesothelioma.  How the New Mesothelioma Immunotherapy Trial Will Work Opdivo is the brand name for nivolumab. It blocks a protein called PD-1 in cancer cells. PD-1 is one of the ways that mesothelioma cells evade the immune system. Opdivo is often … Continue reading New Mesothelioma Immunotherapy Trial Now Underway at Baylor »